This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

PROGENICS PHARMACEUTICAL INC's gross profit margin for the fourth quarter of its fiscal year 2014 has significantly increased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. PROGENICS PHARMACEUTICAL INC is extremely liquid. Currently, the Quick Ratio is 17.86 which clearly shows the ability to cover any short-term cash needs. PGNX managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 58.15% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.

Income Statement

Q4 FY14

Q4 FY13

Net Sales ($mil)

-0.57

2.97

EBITDA ($mil)

-10.63

-7.64

EBIT ($mil)

-10.75

-7.8

Net Income ($mil)

-12.18

-8.55

Balance Sheet

Q4 FY14

Q4 FY13

Cash & Equiv. ($mil)

119.3

65.86

Total Assets ($mil)

161.04

114.54

Total Debt ($mil)

0.0

0.0

Equity ($mil)

124.91

78.98

Profitability

Q4 FY14

Q4 FY13

Gross Profit Margin

1861.3

-257.38

EBITDA Margin

1861.29

-257.37

Operating Margin

1883.36

-262.94

Sales Turnover

0.28

0.07

Return on Assets

2.73

-37.16

Return on Equity

3.53

-53.9

Debt

Q4 FY14

Q4 FY13

Current Ratio

0.0

10.67

Debt/Capital

0.0

0.0

Interest Expense

0.0

0.0

Interest Coverage

0.0

0.0

Share Data

Q4 FY14

Q4 FY13

Shares outstanding (mil)

69.56

60.83

Div / share

0.0

0.0

EPS

-0.18

-0.14

Book value / share

1.8

1.3

Institutional Own %

n/a

n/a

Avg Daily Volume

861842.0

1116773.0

Valuation

SELL. PROGENICS PHARMACEUTICAL INC's P/E ratio indicates a significant premium compared to an average of 46.06 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 19.41. Conducting a second comparison, its price-to-book ratio of 3.18 indicates a premium versus the S&P 500 average of 2.74 and a significant discount versus the industry average of 11.94. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.

Price/Earnings

1

2

3

4

5

premium

discount

Price/Cash Flow

1

2

3

4

5

premium

discount

PGNX 571.00

Peers 46.06

PGNX NA

Peers 59.57

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

PGNX is trading at a significant premium to its peers.

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

Price/Projected Earnings

1

2

3

4

5

premium

discount

Price toEarnings/Growth

1

2

3

4

5

premium

discount

PGNX 190.33

Peers 30.35

PGNX NM

Peers 0.62

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.